10 results about "Romidepsin" patented technology

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

The invention relates to the technical field of gene engineering, in particular to an HDR enhancer for improving cell homologous recombination efficiency and application of the HDR enhancer, and the HDR enhancer for improving the cell homologous recombination efficiency comprises an inhibitor of a non-homologous end connection repair pathway and an intracellular homologous recombination accelerant; the inhibitors of the non-homologous end connection repair pathway are SCR-7 and M3814, the intracellular homologous recombination accelerators are L755507 and Romidepsin, the four agents synergistically target an NHEJ signal pathway, the cell cycle, chromatin structure opening and HDR signal pathway are regulated and controlled at the same time, and the problem that an existing reagent for improving the cell homologous recombination efficiency is insufficient in synergistic effect is solved.

The invention relates to the field of biomedicine, in particular to a protein polypeptide combined with type I histone deacetylase (HDACs) and capable of improving the solid tumor resisting curative effect of an HDAC inhibitor. The protein polypeptide combined with the I-type HDACs is developed on the basis of a liver-type phosphofructokinase (PFKL) protein sequence, the protein polypeptide is directly combined with the I-type HDACs through a Thr562 site, the targeting chelation stability of an HDAC inhibitor Romidepsin on zinc ions in the HDACs is promoted, and the anti-tumor drug effect of the Romidepsin can be remarkably improved. The invention provides an effective tool for solving the problem of insufficient curative effect of the HDAC inhibitor Romidepsin in solid tumors at present, and has good clinical application value.

The invention provides a salt / eutectic crystal of romidepsin and a preparation method and application thereof, the salt / eutectic crystal is 1, 5-naphthalene disulfonate / eutectic crystal of romidepsin, and the salt / eutectic crystal has characteristic peaks at 2 theta values of 7.6 degrees + / -0.2 degrees, 15.4 degrees + / -0.2 degrees, 19.9 degrees + / -0.2 degrees, 21.1 degrees + / -0.2 degrees and 22.9 degrees + / -0.2 degrees by using X-ray powder diffraction of Cu-K alpha radiation. The 1, 5-naphthalene disulfonate / eutectic crystal of the romidepsin has good physical and chemical stability and high yield, has obvious advantages in at least one aspect of solubility, anti-cancer effect, hygroscopicity, stability, mechanical stability, fluidity, compressibility, adhesiveness and the like, provides a new better choice for preparation of a medicinal preparation containing the romidepsin, and has wide application prospects. And the method has very important significance on drug development.

The application provides application of a ZNF652 gene as a marker in preparation of a kit for evaluating cancer occurrence risk and / or prognosis, wherein the ZNF652 gene as the marker comprises transcription of ZNF652 and / or loss of heterozygosity (LOH) of ZNF652. Further provided is use of a ZNF652 gene expression detection reagent in preparation of a kit for guiding anti-PD-L1 immunotherapy and guiding combination use of an anti-PD-L1 antibody. Further provided is use of an HDAC inhibitor romidepsin combined with an anti-PD-L1 antibody in preparation of a breast cancer treatment drug. The application provides an important theoretical basis for evaluating occurrence risk, treatment and prognosis of clinical triple-negative breast cancer.

Provided are compositions that include histone deacetylase (HDAC) inhibitors encapsulated in and / or otherwise associated with detectable nanoparticles, and methods for using the same in medical and veterinary applications including but not limited to treating diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors; inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to HDAC inhibitors, and for treating inflammatory and / or an autoimmune diseases, disorders, and / or conditions associated with sensitivity to HDAC inhibitors. Also provided are methods for imaging cells, tissues, organs, and / or other targets in subject.

The present application belongs to the field of microbial genetic engineering technology, and particularly relates to tumor-targeting drug-producing engineering strains and a construction method and application thereof. The present application discloses a series of tumor-targeting drug-producing engineering strains, which can produce the anticancer drug romidepsin in situ in a tumor, can heterologously express romidepsin, and can produce romidepsin in situ in a tumor of a tumor-bearing small animal and has the activity of inhibiting tumor growth. That is, the present application provides a series of Escherichia coli Nissle 1917 recombinant strains, which are expected to become an anticancer live bacterial drug and will be applied to the clinic in the future, and therefore have good practical application value.

The invention belongs to the technical field of application of pre-sensitization rejection drugs, and particularly relates to an application method of romidepsin in a pre-sensitization rejection drug. According to the application, by controlling the use mode of the romidepsin, the effects of inhibiting HDAC1 and HDAC2 by using the romidepsin are realized, the acetylation levels of different sites corresponding to histone H2A and H3 are up-regulated, the expression of BLIMP-1, AID and the like is reduced, the activity of an endoplasmic reticulum IRE1alpha-XBP1 pathway is inhibited, the transcriptional levels of Pridm1 and Xbp1 are further reduced, the generation of plasma cells is inhibited, the generation of donor specific antibodies is reduced, and the application of the romidepsin in the preparation of the medicine for treating the endoplasmic reticulum IRE1alpha-XBP1 is promoted. The synthetic secretion of antibodies is inhibited, thereby improving the survival of the graft.

The present invention includes a method to increase romidepsin concentration in a bacteria fermentation media. Romidepsin concentration in a fermentation is increased by adding, for example, copper sulfate. The end resulting romidepsin concentration is increased by at least about two fold as compare to fermentation without copper sulfate.

The invention belongs to the technical field of biological medicine, and relates to a medicine composition containing norcantharidin and application of the medicine composition in preparation of a medicine for treating triple negative breast cancer. The invention relates to a pharmaceutical composition containing norcantharidin. The composition comprises norcantharidin and an HDAC (histone deacetylase) inhibitor, wherein the HDAC inhibitor is vorinostat, belinostat, panobinostat, romidepsin or chidamide. The norcantharidin pharmaceutical composition provided by the invention contains norcantharidin and an HDAC (histone deacetylase) inhibitor vorinostat SAHA, romidepsin FK228, belinostat PXD101, panobinostat LBH589 and chidamide, and the composition can be used for remarkably inhibiting the proliferation of triple negative breast cancer cells. The composition can be developed into an anti-breast cancer drug combination scheme or preparation.